Any current/future new fundraising through debt or equity?

There is no direct mention of any current or planned fundraising through equity in the transcript. On debt, it is noted that Cupid Limited has short-term borrowings of around Rs. 8 crores, down from Rs. 11-12 crores previously, primarily for working capital. There is no explicit discussion of new debt or equity fundraising plans in the call. The management mentioned being open to exploring excellent opportunities, but no specific fundraising initiatives were indicated. Overall, the transcript does not reveal any current or future fundraising through debt or equity being planned or underway.

Future growth expectations in sales/revenue/volumes?

Cupid Limited aims to double its revenue in the next 2-3 years through development and expansion plans. FY22 revenue target is approximately Rs.150 crores, with a PAT of at least Rs.20 crores. FY23 revenue is expected to range between Rs.170-180 crores, driven partly by diagnostics sales, targeting a minimum 20% PAT margin. Capacity utilization is strong, with 98% for male condoms and 97% for female condoms. The company anticipates commercial production for IVD diagnostics starting Q4 FY22, expanding business verticals. US market entry is expected to generate a minimum $5 million in

Future growth expectations in earnings/operating earnings/profits/EPS?

Cupid Limited aims to double revenue in the next 2-3 years through expansion and a new CEO with international marketing, production, and financial expertise. For FY22, expected revenue is around Rs.150 crores with a PAT minimum of Rs.20 crores. For FY23, revenue is projected between Rs.170-180 crores with a net profit margin target of at least 20%. US market entry expected to generate a minimum of $5 million in first-year revenue with 30-40% net profit margin. Diagnostic (IVD) business commercial production to start Q4 FY22, expected to contribute to revenue growth. Marketing budget

Current/ Expected Orderbook/ Pending Orders?

Current order book is about Rs. 71 crores. Expecting allocations from major tenders in Tanzania, South Africa, and Indian Government. South Africa tender allocation expected in November 2021, involving 1 billion male condoms and 40 million female condoms per year for the next 3 years. Awaiting new tender from Brazil expected early next year due to government budget cuts affecting current procurement. Planning to participate in all tenders and explore export markets. Established contacts with major buyers of IVD products, including potential outsourcing to major players like Mylan.

IN US

Sale is live|00:00:00left today

Cupid LtdQ3 FY21Personal Products

Cupid Ltd Q3 FY21 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹183P/E: 149.5Market Cap: ₹16.2K CrSector: Personal Products

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

Yes

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Cupid Limited aims to double its revenue in the next 2-3 years through development and expansion plans.
→FY22 revenue target is approximately Rs.150 crores, with a PAT of at least Rs.20 crores.
→FY23 revenue is expected to range between Rs.170-180 crores, driven partly by diagnostics sales, targeting a minimum 20% PAT margin.
→Capacity utilization is strong, with 98% for male condoms and 97% for female condoms.
→The company anticipates commercial production for IVD diagnostics starting Q4 FY22, expanding business verticals.
→US market entry is expected to generate a minimum $5 million in the first year with 30-40% profit margins; Cupid will be the second player after Veru Pharma.
→Marketing budget for female condoms in India may double, responding to slow domestic demand but significant growth potential.
→Tender opportunities in Tanzania, South Africa, and India are expected to add substantial volume.

Margin guidance

Category 1

→Cupid Limited aims to double revenue in the next 2-3 years through expansion and a new CEO with international marketing, production, and financial expertise.
→For FY22, expected revenue is around Rs.150 crores with a PAT minimum of Rs.20 crores.
→For FY23, revenue is projected between Rs.170-180 crores with a net profit margin target of at least 20%.
→US market entry expected to generate a minimum of $5 million in first-year revenue with 30-40% net profit margin.
→Diagnostic (IVD) business commercial production to start Q4 FY22, expected to contribute to revenue growth.
→Marketing budget likely to double in coming years to boost female condom sales, addressing low current domestic demand.
→Expansion to government tenders and export markets (e.g., Tanzania, South Africa) expected to provide significant order inflows.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no direct mention of any current or planned fundraising through equity in the transcript.
→On debt, it is noted that Cupid Limited has short-term borrowings of around Rs. 8 crores, down from Rs. 11-12 crores previously, primarily for working capital.
→There is no explicit discussion of new debt or equity fundraising plans in the call.
→The management mentioned being open to exploring excellent opportunities, but no specific fundraising initiatives were indicated.
→Overall, the transcript does not reveal any current or future fundraising through debt or equity being planned or underway.

Order book

Yes

→Current order book is about Rs. 71 crores.
→Expecting allocations from major tenders in Tanzania, South Africa, and Indian Government.
→South Africa tender allocation expected in November 2021, involving 1 billion male condoms and 40 million female condoms per year for the next 3 years.
→Awaiting new tender from Brazil expected early next year due to government budget cuts affecting current procurement.
→Planning to participate in all tenders and explore export markets.
→Established contacts with major buyers of IVD products, including potential outsourcing to major players like Mylan.

Capex plans

Yes

- Cupid Limited has recently completed construction of a new diagnostics plant at Nasik. - Commercial production from the Nasik IVD (In Vitro Diagnostics) facility is expected to start from Q4 FY22. - The company is setting up instruments and starting experimental production in December 2021. - There have been delays in the commissioning of this plant due to supply chain and COVID-related labor/material shortages. - Cupid is exploring marketing plans and partnerships to boost the diagnostics vertical and considering use of tele-marketing for female condoms. - No explicit mention of other specific capex or strategic investments in the transcript, but emphasis is on production expansion, doubling revenue in next 2-3 years from existing and new product lines. - The company is increasing marketing budgets for female condoms, expected to be doubled depending on market response. In summary, the main current/future capital investment is in the diagnostics (IVD) plant at Nasik and related expansion activities.

How does Cupid Ltd rank vs peers in Personal Products?

Pro feature

1Cupid Ltd

Rev 2Mar 1

See full Personal Products sector rankings

Want more stocks like Cupid Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio